20.03.2024 14:34:57
|
Scilex, Takeda Settle Paragraph IV Patent Infringement Lawsuit - Quick Facts
(RTTNews) - Scilex Holding Company (SCLX) announced that the company and its subsidiary, Scilex Pharmaceuticals, have entered into a settlement agreement with Takeda Pharmaceuticals U.S.A., and Takeda Pharmaceuticals Company to resolve the Paragraph IV patent infringement lawsuit that Takeda filed against the Scilex Parties in federal district court in Delaware in November 2023. The Scilex Parties entered into a License Agreement with Takeda granting Scilex Holding Company and its affiliates a non-exclusive license to certain patents owned by Takeda.
The litigation was related to Scilex's filing of a sNDA with the FDA seeking to expand the label for FDA-approved liquid colchicine product, Gloperba, a preventive treatment for gout.
For More Such Health News, visit rttnews.com.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Takeda Pharmaceutical Co Ltd. (spons. ADRs)mehr Nachrichten
30.10.24 |
Ausblick: Takeda Pharmaceutical präsentiert Quartalsergebnisse (finanzen.net) | |
16.10.24 |
Erste Schätzungen: Takeda Pharmaceutical mit Zahlen zum abgelaufenen Quartal (finanzen.net) | |
30.07.24 |
Ausblick: Takeda Pharmaceutical stellt das Zahlenwerk zum vergangenen Quartal vor (finanzen.net) | |
16.07.24 |
Erste Schätzungen: Takeda Pharmaceutical präsentiert Quartalsergebnisse (finanzen.net) |
Analysen zu Takeda Pharmaceutical Co Ltd. (spons. ADRs)mehr Analysen
Aktien in diesem Artikel
Scilex Holding Company Registered Shs | 0,51 | -1,42% | |
Takeda Pharmaceutical Co Ltd. (spons. ADRs) | 12,80 | 0,00% |